scholarly journals Differential cardiotoxic electrocardiographic response to doxorubicin treatment in conscious versus anesthetized mice

2021 ◽  
Vol 9 (15) ◽  
Author(s):  
Anna Warhol ◽  
Sharon A. George ◽  
Sofian N. Obaid ◽  
Tatiana Efimova ◽  
Igor R. Efimov
Keyword(s):  
Doxorubicin Treatment

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.

1995 ◽  
Vol 13 (8) ◽  
pp. 2056-2065 ◽  
Author(s):  
J S Abrams ◽  
D A Vena ◽  
J Baltz ◽  
J Adams ◽  
M Montello ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Progressive Disease ◽  
Overall Response Rate ◽  
Metastatic Breast ◽  
Investigational Drug ◽  
Single Institution ◽  
Doxorubicin Treatment ◽  
Heavily Pretreated ◽  
Pretreated Patients

PURPOSE To provide paclitaxel, an investigational drug at the inception of this study, to women with chemotherapy-refractory metastatic breast cancer and to evaluate response and toxicity in these patients. PATIENTS AND METHODS Two hundred sixty-seven patients with progressive disease (PD) following at least two chemotherapy regimens for metastatic breast cancer and a contraindication to further doxorubicin treatment received paclitaxel either at 175 mg/m2 intravenously (IV) over 24 hours or at 135 mg/m2 if they had prior irradiation to 30% of marrow-bearing bone or a cumulative dose of mitomycin > or = 20 mg/m2. RESULTS In a subgroup of patients (n = 172) with measurable disease, four complete responses (CRs) and 36 partial responses (PRs) occurred, for an overall response rate of 23% (95% confidence interval [CI], 17% to 30%). No differences in response rates were noted according either to the number of prior chemotherapy regimens received or to whether patients were considered refractory to doxorubicin. The dose and schedule used in this trial resulted in febrile neutropenia in 45% of patients and a hospitalization rate of 49%. CONCLUSION Paclitaxel's activity in this multiinstitutional trial in heavily pretreated patients confirms the encouraging results attained in single-institution trials. Although at this dose and schedule paclitaxel may be considered too myelosuppressive for palliative care, supportive measures such as colony-stimulating factors and antibiotics were not used prophylactically. Current research efforts are focusing on whether paclitaxel's activity against breast cancer is dose- and/or schedule-dependent, and on what role it has in patients with less advanced disease.

scholarly journals HMGB1 orchestrates STING-mediated senescence via TRIM30α modulation in cancer cells

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Je-Jung Lee ◽  
In Ho Park ◽  
Man Sup Kwak ◽  
Woo Joong Rhee ◽  
Songhee H. Kim ◽  
...  
Keyword(s):  
High Mobility ◽  
Dependent Manner ◽  
Signal Transducer ◽  
Therapeutic Concept ◽  
Doxorubicin Treatment ◽  
Tripartite Motif ◽  
Anticancer Mechanism ◽  
Tripartite Motif Protein ◽  
Underlying Mechanisms ◽  
Novel Therapeutic

AbstractAlthough cellular senescence has emerged as a novel therapeutic concept in cancer, its underlying mechanisms remain unclear. High mobility group box 1 (HMGB1) and stimulator of interferon genes (STING) are involved in senescence. However, their interactions in senescence have not been reported. Therefore, in this study, we investigated the relationships between HMGB1 and STING in senescence in cancer and other cells. In mouse melanoma cells and several other cell lines, doxorubicin treatment induced senescence in an HMGB1-dependent manner. These responses were mediated by STING, and this function of STING was negatively regulated by the E3 ligase tripartite motif protein 30α (TRIM30α). We also found that HMGB1 bound to the TRIM30α promoter and then suppressed its expression by inhibiting its transcription, which enhanced STING-induced senescence. This mechanism was further mediated by signal transducer and activator of transcription 6 (STAT6) and p21. Overall, our findings demonstrated that HMGB1 orchestrated STING-STAT6-p21-mediated senescence by regulating TRIM30α as an alternative anticancer mechanism.

Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat

1999 ◽  
Vol 26 (7-8) ◽  
pp. 785-800 ◽  
Author(s):  
Florence Dalloz ◽  
Philippe Maingon ◽  
Yves Cottin ◽  
François Briot ◽  
Jean-Claude Horiot ◽  
...  
Keyword(s):  
Cardiac Function ◽  
Antioxidant Defenses ◽  
Doxorubicin Treatment

scholarly journals In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment

2005 ◽  
Vol 12 (6) ◽  
pp. 649-658 ◽  
Author(s):  
A J Quesada ◽  
T Nelius ◽  
R Yap ◽  
T A Zaichuk ◽  
A Alfranca ◽  
...  
Keyword(s):  
Doxorubicin Treatment ◽  
Synergistic Inhibition ◽  
Inhibition Of Angiogenesis

scholarly journals P147Protective effect of ubiquinone-10 and complex of precursors and modulator of its biosynthesis on heart under doxorubicin treatment

2014 ◽  
Vol 103 (suppl 1) ◽  
pp. S26.1-S26
Author(s):  
O Kuchmenko ◽  
A Burlaka ◽  
I Ganusevich
Keyword(s):  
Doxorubicin Treatment ◽  
Ubiquinone 10

scholarly journals miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e50469 ◽  
Author(s):  
Florian Kopp ◽  
Prajakta S. Oak ◽  
Ernst Wagner ◽  
Andreas Roidl
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Doxorubicin Treatment ◽  
Bmi1 Expression

34 MicroRNA-221 TARGETS PUMA AND SENSITIZES HUMAN HEPATOCELLULAR CARCINOMA CELLS TO DOXORUBICIN TREATMENT

2010 ◽  
Vol 42 ◽  
pp. S14
Author(s):  
F. Fornari ◽  
L. Gramantieri ◽  
M. Milazzo ◽  
D. Pollutri ◽  
G.L. Grazi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Carcinoma Cells ◽  
Human Hepatocellular Carcinoma ◽  
Doxorubicin Treatment ◽  
Hepatocellular Carcinoma Cells ◽  
Human Hepatocellular Carcinoma Cells

scholarly journals Synthesis and Biological Evaluation of New 3,4-diarylmaleimides as Enhancers (modulators) of Doxorubicin Cytotoxic Activity on Cultured Tumor Cells from a Real Case of Breast Cancer

2017 ◽  
Vol 61 (1) ◽  
Author(s):  
Jessica R. Gutierrez-Cano ◽  
Pradip D. Nahide ◽  
Velayudham Ramadoss ◽  
Yuvraj Satkar ◽  
Rafael Ortiz-Alvarado ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cultured Cells ◽  
Biological Evaluation ◽  
Doxorubicin Treatment ◽  
P Glycoprotein ◽  
Molecular Action ◽  
Mortality Effect ◽  
Kinase Phosphorylation ◽  
Synthesis And Biological Evaluation ◽  
Cultured Tumor Cells

<p>A series of new 3,4-diarylmaleimides were synthesized in an optimized and efficient lineal sequence of three steps, starting from commercial maleimide. The biological evaluation of these compounds as enhancers (activity modulators) in the co-administration with doxorubicin treatment in breast cancer cells directly obtained from a patient, were essayed. The cancerous tissue BT026-512N was provided by the National Institute of Cancerology (INCAN) of México. This tissue was obtained by biopsy from a patient diagnosed with stage IIB ductal breast cancer. The results obtained in the assays, show decreased cell viability on the cultured cells for all of the maleimides synthesized in combinatorial administration with doxorubicin. The highest mortality effect was determined for maleimides <strong>9</strong> and <strong>29</strong> increased in close to three times the effect compared with treatment using only doxorubicin. Based on previous functionalized maleimides core reports and Molinspiration chemoinformatic analysis, these results could possibly point out to the Pg-p glycoprotein as bio-molecular action target of maleimides by kinase phosphorylation-inhibition, although more experimental data is necessary.</p>

The effect of Deoxyelephantopin enhances Doxorubicin Sensitivity to MCF-7 Cancer Cells

2021 ◽  
pp. 2791-2795
Author(s):  
Frengki Frengki ◽  
Deddi P. Putra ◽  
Fatma Sri Wahyuni ◽  
Daan Khambri ◽  
Vivi Sofia
Keyword(s):  
Synergistic Effect ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Blue Staining ◽  
Doxorubicin Treatment ◽  
Combination Treatments ◽  
Mtt Method ◽  
Diphenyltetrazolium Bromide ◽  
Number Of Cells ◽  
Mcf 7

Deoxyelephantopin is a lactone sesquiterpene compound that shows toxic effects on some cancer cells, otherwise, it is safe on normal cells. The combination of chemotherapy with this compound is intended to determine its effect in increasing the sensitivity of chemotherapy to MCF-7 cancer cells. Cell viability was determined through the MTT method (3-(4,5-dimethyl thiazol-2-il) -2,5-diphenyltetrazolium bromide) to determine the combined effect, while the number of cell deaths was determined through trypan blue staining. Giving deoxyelephantopin-doxorubicin combination to MCF-7 cells showed a synergistic effect with a CI < 0.7. The number of cells that died in the 1.52x and 2.12x combination treatments was higher than the single doxorubicin treatment each at IC50 and ½ IC50 concentrations, this confirms the synergistic effect of the combination. This research proves that deoxyelephantopin can increase the sensitivity and effectiveness of doxorubicin chemotherapy against MCF-7 breast cancer cells.

scholarly journals Resistance Exercise And Doxorubicin Treatment: Effects On Antioxidant Enzyme Expression In Type Ii Muscle

2019 ◽  
Vol 51 (Supplement) ◽  
pp. 500
Author(s):  
Salaheddin Sharif ◽  
David S. Hydock ◽  
Kelsey A. Daehlin ◽  
Mackenzie D. Twaddle ◽  
Allison T. Tigner ◽  
...  
Keyword(s):  
Resistance Exercise ◽  
Antioxidant Enzyme ◽  
Treatment Effects ◽  
Type Ii ◽  
Enzyme Expression ◽  
Doxorubicin Treatment
Sign in / Sign up

Export Citation Format

Share Document